在资源贫乏环境中推进眼科保健的人工智能:评估印度糖尿病视网膜病变筛查人工智能模型的预测准确性

Rohan Chawla , Prachi Karkhanis , Malay Shah , Aritra Das , Rishabh Sharma , Dhwani Almaula , Pradeep Venkatesh , Harsh Vardhan Singh , Mukul Kumar , Ramanuj Samanta , Vinod Kumarl , Amar Shah , Bhavin Vadera , Nakul Jain , Akanksha Sen , Shyamsundar Shreedhar , Vipin Garg , Soma Dhaval , Kowshik Ganesh , Srinivas Rana , Radhika Tandon
{"title":"在资源贫乏环境中推进眼科保健的人工智能:评估印度糖尿病视网膜病变筛查人工智能模型的预测准确性","authors":"Rohan Chawla ,&nbsp;Prachi Karkhanis ,&nbsp;Malay Shah ,&nbsp;Aritra Das ,&nbsp;Rishabh Sharma ,&nbsp;Dhwani Almaula ,&nbsp;Pradeep Venkatesh ,&nbsp;Harsh Vardhan Singh ,&nbsp;Mukul Kumar ,&nbsp;Ramanuj Samanta ,&nbsp;Vinod Kumarl ,&nbsp;Amar Shah ,&nbsp;Bhavin Vadera ,&nbsp;Nakul Jain ,&nbsp;Akanksha Sen ,&nbsp;Shyamsundar Shreedhar ,&nbsp;Vipin Garg ,&nbsp;Soma Dhaval ,&nbsp;Kowshik Ganesh ,&nbsp;Srinivas Rana ,&nbsp;Radhika Tandon","doi":"10.1016/j.gloepi.2025.100209","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Timely identification and treatment of Diabetic Retinopathy (DR) is critical in avoiding vision loss. DR screening is challenging, especially in resource-limited areas where trained ophthalmologists are scarce. AI solutions show promise in addressing this challenge. In this study, the performance metrics of an AI solution (MadhuNetrAI) developed in India was evaluated for referring and grading DR.</div></div><div><h3>Methods</h3><div>MadhuNetrAI was developed de novo by the All India Institute of Medical Sciences (AIIMS) and Wadhwani AI (WIAI). It was tested on 1078 fundus images (from AIIMS Delhi and an unannotated subset of publicly available EyePACS images) against two ophthalmologists and an adjudicator serving as independent gold-standard annotators, wherein the disease status of the patients remained unknown.</div></div><div><h3>Findings</h3><div>MadhuNetrAI demonstrated high sensitivity (93·2 %; CI: 89·5 %–95·6 %) and specificity (95·3 %; CI: 93·7 %–96·6 %) in detecting referable DR (moderate, severe, proliferative DR). The area-under-the-curve for referring DR against the gold standard was 0·97 (CI: 0·95–0·99) indicating excellent diagnostic performance. The agreement in grading DR severity was high (kappa = 0·89, CI: 0·86–0·91). The model performed comparably in detecting DR too.</div></div><div><h3>Interpretation</h3><div>MadhuNetrAI's ability to grade DR severity and identify referrable cases could bring DR patients to care much earlier. Further research and clinical trials are needed to ensure its reliability and generalizability across diverse populations and image qualities.</div></div><div><h3>Funding</h3><div>MadhuNetrAI was developed by technical and programmatic teams at WIAI, with inputs and contributions by the clinical team at AIIMS, and funded by USAID. The authors have no financial or non-financial conflicts of interest to disclose.</div></div>","PeriodicalId":36311,"journal":{"name":"Global Epidemiology","volume":"9 ","pages":"Article 100209"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Artificial intelligence for advancing eye care in resource-poor settings: Assessing the predictive accuracy of an AI-model for diabetic retinopathy screening in India\",\"authors\":\"Rohan Chawla ,&nbsp;Prachi Karkhanis ,&nbsp;Malay Shah ,&nbsp;Aritra Das ,&nbsp;Rishabh Sharma ,&nbsp;Dhwani Almaula ,&nbsp;Pradeep Venkatesh ,&nbsp;Harsh Vardhan Singh ,&nbsp;Mukul Kumar ,&nbsp;Ramanuj Samanta ,&nbsp;Vinod Kumarl ,&nbsp;Amar Shah ,&nbsp;Bhavin Vadera ,&nbsp;Nakul Jain ,&nbsp;Akanksha Sen ,&nbsp;Shyamsundar Shreedhar ,&nbsp;Vipin Garg ,&nbsp;Soma Dhaval ,&nbsp;Kowshik Ganesh ,&nbsp;Srinivas Rana ,&nbsp;Radhika Tandon\",\"doi\":\"10.1016/j.gloepi.2025.100209\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Timely identification and treatment of Diabetic Retinopathy (DR) is critical in avoiding vision loss. DR screening is challenging, especially in resource-limited areas where trained ophthalmologists are scarce. AI solutions show promise in addressing this challenge. In this study, the performance metrics of an AI solution (MadhuNetrAI) developed in India was evaluated for referring and grading DR.</div></div><div><h3>Methods</h3><div>MadhuNetrAI was developed de novo by the All India Institute of Medical Sciences (AIIMS) and Wadhwani AI (WIAI). It was tested on 1078 fundus images (from AIIMS Delhi and an unannotated subset of publicly available EyePACS images) against two ophthalmologists and an adjudicator serving as independent gold-standard annotators, wherein the disease status of the patients remained unknown.</div></div><div><h3>Findings</h3><div>MadhuNetrAI demonstrated high sensitivity (93·2 %; CI: 89·5 %–95·6 %) and specificity (95·3 %; CI: 93·7 %–96·6 %) in detecting referable DR (moderate, severe, proliferative DR). The area-under-the-curve for referring DR against the gold standard was 0·97 (CI: 0·95–0·99) indicating excellent diagnostic performance. The agreement in grading DR severity was high (kappa = 0·89, CI: 0·86–0·91). The model performed comparably in detecting DR too.</div></div><div><h3>Interpretation</h3><div>MadhuNetrAI's ability to grade DR severity and identify referrable cases could bring DR patients to care much earlier. Further research and clinical trials are needed to ensure its reliability and generalizability across diverse populations and image qualities.</div></div><div><h3>Funding</h3><div>MadhuNetrAI was developed by technical and programmatic teams at WIAI, with inputs and contributions by the clinical team at AIIMS, and funded by USAID. The authors have no financial or non-financial conflicts of interest to disclose.</div></div>\",\"PeriodicalId\":36311,\"journal\":{\"name\":\"Global Epidemiology\",\"volume\":\"9 \",\"pages\":\"Article 100209\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Epidemiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590113325000276\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590113325000276","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景及时发现和治疗糖尿病视网膜病变(DR)是避免视力丧失的关键。DR筛查具有挑战性,特别是在资源有限、训练有素的眼科医生稀缺的地区。人工智能解决方案有望解决这一挑战。在本研究中,对印度开发的人工智能解决方案(MadhuNetrAI)的性能指标进行评估,以参考和评分博士。方法MadhuNetrAI由全印度医学科学研究所(AIIMS)和Wadhwani AI (WIAI)重新开发。在1078张眼底图像(来自AIIMS Delhi和公开可用的EyePACS图像的未注释子集)上,对两名眼科医生和一名作为独立金标准注释者的审稿人进行了测试,其中患者的疾病状态仍然未知。发现smadhunetrai具有高灵敏度(93.2%;CI: 89.5% - 95.6%)和特异性(95.3%;CI: 93.7% - 96%)在发现可参考DR(中度、重度、增殖性DR)方面。参照金标准的DR曲线下面积为0.97 (CI: 0.95 ~ 0.99),诊断效果良好。对DR严重程度分级的一致性较高(kappa = 0.89, CI: 0.86 ~ 0.91)。该模型在检测DR方面也有相当的效果。madhunetrai分级DR严重程度和识别转诊病例的能力可以使DR患者更早接受治疗。需要进一步的研究和临床试验来确保其在不同人群和图像质量中的可靠性和普遍性。madhunetrai由WIAI的技术和项目团队开发,AIIMS的临床团队提供投入和贡献,并由美国国际开发署资助。作者没有财务或非财务利益冲突要披露。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Artificial intelligence for advancing eye care in resource-poor settings: Assessing the predictive accuracy of an AI-model for diabetic retinopathy screening in India

Background

Timely identification and treatment of Diabetic Retinopathy (DR) is critical in avoiding vision loss. DR screening is challenging, especially in resource-limited areas where trained ophthalmologists are scarce. AI solutions show promise in addressing this challenge. In this study, the performance metrics of an AI solution (MadhuNetrAI) developed in India was evaluated for referring and grading DR.

Methods

MadhuNetrAI was developed de novo by the All India Institute of Medical Sciences (AIIMS) and Wadhwani AI (WIAI). It was tested on 1078 fundus images (from AIIMS Delhi and an unannotated subset of publicly available EyePACS images) against two ophthalmologists and an adjudicator serving as independent gold-standard annotators, wherein the disease status of the patients remained unknown.

Findings

MadhuNetrAI demonstrated high sensitivity (93·2 %; CI: 89·5 %–95·6 %) and specificity (95·3 %; CI: 93·7 %–96·6 %) in detecting referable DR (moderate, severe, proliferative DR). The area-under-the-curve for referring DR against the gold standard was 0·97 (CI: 0·95–0·99) indicating excellent diagnostic performance. The agreement in grading DR severity was high (kappa = 0·89, CI: 0·86–0·91). The model performed comparably in detecting DR too.

Interpretation

MadhuNetrAI's ability to grade DR severity and identify referrable cases could bring DR patients to care much earlier. Further research and clinical trials are needed to ensure its reliability and generalizability across diverse populations and image qualities.

Funding

MadhuNetrAI was developed by technical and programmatic teams at WIAI, with inputs and contributions by the clinical team at AIIMS, and funded by USAID. The authors have no financial or non-financial conflicts of interest to disclose.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Global Epidemiology
Global Epidemiology Medicine-Infectious Diseases
CiteScore
5.00
自引率
0.00%
发文量
22
审稿时长
39 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信